{{위키데이터 속성 추적}}
{{Infobox drug
| drug_name         = 
| INN               = 리파마이신
| type              = <!-- empty -->
| image             = Rifamycin SV.svg
| image2            = Rifamycin SV stick 6BEB.png
| width             = 
| alt               = 
| caption           = 
<!-- Clinical data -->
| pronounce         = 
| tradename         = Aemcolo
| Drugs.com         = {{drugs.com|monograph|rifamycin-sodium}}
| MedlinePlus       = a619010
| licence_CA        = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| licence_EU        = <!-- EMA uses INN (or special INN_EMA) -->
| DailyMedID        = Rifamycin
| licence_US        = Aemcolo
| pregnancy_AU      = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_AU_comment = 
| pregnancy_US      = N
| pregnancy_US_comment = 
| pregnancy_category= 
| dependency_liability = 
| addiction_liability = 
| routes_of_administration = By mouth
| class             = 
| ATCvet            = 
| ATC_prefix        = A07
| ATC_suffix        = AA13
| ATC_supplemental  = {{ATC|S01|AA16}} {{ATC|S02|AA12}} {{ATC|J04|AB03}} {{ATC|D06|AX15}}
<!-- Legal status -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment = 
| legal_BR =  <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment = 
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment = 
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment = 
| legal_US = Rx-only
| legal_US_comment = 
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_UN_comment = 
| legal_status      = <!--For countries not listed above-->
<!-- Identifiers -->
| index2_label = as salt
| CAS_number        = 6998-60-3
| CAS_supplemental  = 
| PubChem           = 6324616
| PubChemSubstance  = 
| IUPHAR_ligand     = 
| DrugBank          = DB11753
| ChemSpiderID      = 16735998
| UNII              = DU69T8ZZPA
| KEGG              = D02549
| KEGG2             = D08480
| ChEBI             = 29673
| ChEMBL            = 437765
| NIAID_ChemDB      = 
| PDB_ligand        = 
| synonyms          = 
<!-- Chemical and physical data -->
| IUPAC_name        = 
| chemical_formula  = 
| C=37 | H=47 | N=1 | O=12
| molecular_weight  = 
| SMILES            = CC1C=CC=C(C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C
| Jmol              = 
| StdInChI          = 1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1
| StdInChI_comment  = 
| StdInChIKey       = HJYYPODYNSCCOU-ODRIEIDWSA-N
| density           = 
| density_notes     = 
| melting_point     = 
| melting_high      = 
| melting_notes     = 
| boiling_point     = 
| boiling_notes     = 
| solubility        = 
| sol_units         = 
| specific_rotation = 
}}

'''리파마이신'''(rifamycin)은 [[항생제]]의 그룹으로, [[아미콜라톱시스 리파마이시니카]](''Amycolatopsis rifamycinica'')라는 세균에서 자연적으로 합성되거나 인공적으로 합성된다. [[안사마이신]]이라고 하는 보다 큰 그룹에 속한다. [[미코박테리아]]에 대해 특히 효과적이며, 따라서 [[결핵]], [[나병]], [[미코박테리움 아비움 복합체]](MAC) 감염 등의 치료에 사용된다.

리파마이신 그룹에는 고전적인 리파마이신 약물과 리파마이신 유도체가 속한다. 리파마이신 유도체에는 [[리팜피신]] (또는 리팜핀), [[리파부틴]], [[리파펜틴]], [[리팔라질]], [[리팍시민]] 등이 있다. 상품명 앰콜로(Aemcolo)로 판매되는 리파마이신은 특정 상황에서의 [[여행자 설사]] 치료용으로 미국에서 그 사용이 승인되었다.<ref>{{저널 인용|last1=Lin|first1=Shu-Wen|last2=Lin|first2=Chun-Jung|last3=Yang|first3=Jyh-Chin|date=August 2017|title=Rifamycin SV MMX for the treatment of traveler's diarrhea|journal=Expert Opinion on Pharmacotherapy|volume=18|issue=12|pages=1269–1277|doi=10.1080/14656566.2017.1353079|issn=1744-7666|pmid=28697313|s2cid=8853242}}</ref><ref>{{보도자료 인용|url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-travelers-diarrhea|title=FDA approves new drug to treat travelers' diarrhea|website=U.S. [[Food and Drug Administration]] (FDA)|date=2018-11-16|access-date=2018-11-19}}</ref><ref>{{웹 인용| title=Drug Approval Package: Aemcolo (rifamycin) | website=U.S. [[Food and Drug Administration]] (FDA) | date=21 December 2018 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210910Orig1_toc.cfm | access-date=27 December 2019}}</ref>

== 각주 ==
{{각주}}

== 외부 링크 ==
* {{웹 인용| url = https://druginfo.nlm.nih.gov/drugportal/name/rifamycin | publisher = U.S. National Library of Medicine| work = Drug Information Portal| title = Rifamycin }}

[[분류:리파마이신| ]]
[[분류:CYP3A4 유도물질]]